Wednesday, July 8, 2026

Patent intelligence · US

US 6872718

Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents

expired A61PA61P13/02A61P25/00A61P25/16
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 1,436
Patent details — US 6872718
Jurisdiction
US
Status
expired
Grant date
Mar 29, 2005
Expiration
Mar 24, 2025
Claims
20
CPC classes
A61P, A61P13/02, A61P25/00, A61P25/16
View on Google Patents ↗

Quick answer

US 6872718 (Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Mar 29, 2005. Expires Mar 24, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61P, A61P13/02, A61P25/00, A61P25/16, A61P25/28, A61P9/08

More from Takeda Chemical Industries Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 6872718?

US 6872718 (Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Mar 29, 2005. Expires Mar 24, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6872718?

Takeda Chemical Industries Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 6872718 expire?

Our index shows an expiration date of Mar 24, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.